Today: 20 May 2026
Browse Category

NASDAQ:UPWK 4 November 2025 - 11 February 2026

Upwork stock wobbles in premarket after 19% slide as Q1 outlook stuns traders

Upwork stock wobbles in premarket after 19% slide as Q1 outlook stuns traders

Upwork shares slipped 0.1% to $15.20 premarket Wednesday after plunging 19% the previous session on weak first-quarter guidance. The company forecast Q1 revenue of $192 million to $197 million, below analyst expectations, and warned of higher costs and pressure in categories hit by AI. RBC, Citizens, and UBS lowered price targets, citing execution risk and uncertainty around enterprise growth.
11 February 2026
·
Upwork stock sinks about 26% in premarket after soft outlook jars investors (UPWK)

Upwork stock sinks about 26% in premarket after soft outlook jars investors (UPWK)

Upwork shares fell about 26% in premarket trading Tuesday to $13.92 after forecasting first-quarter revenue and profit below Wall Street estimates. The company beat fourth-quarter expectations but warned of a softer start to 2026. Active clients dropped to 785,000 at year-end. Upwork cited spending on enterprise and marketing as reasons for lower margin guidance.
10 February 2026
··
Upwork (UPWK) Stock Hits Fresh 52‑Week High: AI Partnerships, Index Inclusion and Q3 Earnings Rewire the 2026 Outlook

Upwork (UPWK) Stock Hits Fresh 52‑Week High: AI Partnerships, Index Inclusion and Q3 Earnings Rewire the 2026 Outlook

Upwork shares hit a new 52-week high of $21.39 on December 11, 2025, lifting its market cap to about $2.46 billion. The stock is up nearly 90% from its yearly low, driven by record Q3 results, new AI partnerships, and entry into the S&P SmallCap 600. Insider selling and high short interest remain. Upwork now posts positive GAAP earnings and a gross margin near 78%.
11 December 2025
····
Upwork Stock Soars on AI-Fueled Earnings Beat – Key Facts & Expert Outlook

Upwork Stock Soars on AI-Fueled Earnings Beat – Key Facts & Expert Outlook

Upwork reported Q3 2025 revenue of $201.7 million, beating estimates, and raised its full-year outlook above consensus. Shares surged nearly 20% to around $17 after the results. Wall Street analysts boosted price targets, with Goldman Sachs setting a $25 target citing AI-driven growth. AI-related freelance work on the platform jumped 53% year-over-year.
4 November 2025
···

Stock Market Today

  • AMD Stock Rises Amid AI Chip Export Speculation and Momentum Trade
    May 20, 2026, 10:09 AM EDT. Advanced Micro Devices (NASDAQ:AMD) gained 2.48% in premarket trading to $424.30, buoyed by positive momentum in growth stocks and hopes of relaxed U.S. AI chip export restrictions to China. AMD trades well above key moving averages, signaling a strong uptrend, although momentum indicators like MACD suggest cooling upside pressure. Analysts maintain a bullish outlook, with average price targets near $447 and recent upgrades from Evercore ISI and Daiwa Capital lifting forecasts up to $579 and $500 respectively. Key resistance stands at $469, near AMD's 52-week high. Heavy ETF exposure could amplify stock moves amid fund flows, making AMD a closely watched semiconductor play amid evolving geopolitical and market conditions.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop